JP2022520671A5 - - Google Patents

Info

Publication number
JP2022520671A5
JP2022520671A5 JP2021569258A JP2021569258A JP2022520671A5 JP 2022520671 A5 JP2022520671 A5 JP 2022520671A5 JP 2021569258 A JP2021569258 A JP 2021569258A JP 2021569258 A JP2021569258 A JP 2021569258A JP 2022520671 A5 JP2022520671 A5 JP 2022520671A5
Authority
JP
Japan
Prior art keywords
valproic acid
pharmaceutically acceptable
acceptable salt
acid compound
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021569258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017352 external-priority patent/WO2020163812A1/en
Publication of JP2022520671A publication Critical patent/JP2022520671A/ja
Publication of JP2022520671A5 publication Critical patent/JP2022520671A5/ja
Withdrawn legal-status Critical Current

Links

JP2021569258A 2019-02-08 2020-02-07 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬 Withdrawn JP2022520671A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803345P 2019-02-08 2019-02-08
US62/803,345 2019-02-08
PCT/US2020/017352 WO2020163812A1 (en) 2019-02-08 2020-02-07 Valproic acid compounds and wnt agonists for treating ear disorders

Publications (2)

Publication Number Publication Date
JP2022520671A JP2022520671A (ja) 2022-03-31
JP2022520671A5 true JP2022520671A5 (enExample) 2023-02-15

Family

ID=69771188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569258A Withdrawn JP2022520671A (ja) 2019-02-08 2020-02-07 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬

Country Status (5)

Country Link
US (1) US20220133740A1 (enExample)
EP (1) EP3920885A1 (enExample)
JP (1) JP2022520671A (enExample)
AU (1) AU2020218366A1 (enExample)
WO (1) WO2020163812A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP1019043A4 (en) 1996-05-07 2003-07-30 Univ Pennsylvania INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
ES2246927T3 (es) 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
WO2001056567A1 (en) 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
JP2001275095A (ja) 2000-03-27 2001-10-05 Sony Corp 通信方法、通信サービス装置、通信端末装置および通信システム
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
DE60129222T2 (de) 2000-05-11 2008-03-06 Consejo Superior de Investigaciónes Científicas Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1360286A2 (en) 2000-09-19 2003-11-12 Chiron Corporation Characterization of the gsk-3beta protein and methods of use thereof
AU2001287898A1 (en) 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
WO2002032896A1 (en) 2000-10-16 2002-04-25 Novo Nordisk A/S Furazanyl-triazole derivates for the treatment of diseases
BR0116468A (pt) 2000-12-08 2004-06-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituìda por indazolila como inibidores de cinase
RU2275373C2 (ru) 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
KR20030076650A (ko) 2001-02-02 2003-09-26 미쯔비시 웰 파마 가부시키가이샤 디하이드로피라졸로피리딘 화합물 및 그의 약학적 용도
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
AU2002363174B2 (en) 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
HUP0402245A3 (en) 2001-11-01 2010-03-29 Janssen Pharmaceutica Nv Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
ATE466581T1 (de) 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
AU2002353186A1 (en) 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
KR20040084896A (ko) 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
CN1630863B (zh) 2002-02-11 2010-06-09 诺华疫苗和诊断公司 人gsk3的结晶方法及其新的晶体结构
AU2003245700A1 (en) 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
ATE368657T1 (de) 2002-03-08 2007-08-15 Lilly Co Eli Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
CA2485527A1 (en) 2002-05-08 2003-11-20 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
ES2312785T3 (es) 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
JP2005531609A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
MXPA05001367A (es) 2002-08-02 2005-04-28 Vertex Pharma Composiciones de pirazol utiles como inhibidores de gsk-3.
EP1739087A1 (en) 2002-08-02 2007-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CA2496246A1 (en) 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
CN1717391A (zh) 2002-10-21 2006-01-04 希龙公司 糖元合成酶激酶3的抑制剂
EP1438942A1 (en) 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
JP2006521386A (ja) 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤である置換ピロリン
US7439363B2 (en) 2003-06-13 2008-10-21 Janssen Parmaceutica N.V. Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors
NZ545058A (en) 2003-07-16 2008-05-30 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
JP2005145928A (ja) 2003-11-19 2005-06-09 Yamanouchi Pharmaceut Co Ltd ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体を有効成分とする医薬組成物
GB0327908D0 (en) 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2005298437A (ja) 2004-04-15 2005-10-27 Astellas Pharma Inc ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体
WO2005123672A2 (en) 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
GB0418328D0 (en) 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
WO2006034207A2 (en) 2004-09-17 2006-03-30 Vanderbilt University Use of gsk3 inhibitors in combination with radiation therapies
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006075023A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
EP1847531A4 (en) 2005-02-09 2009-04-22 Takeda Pharmaceutical PYRAZOLE DERIVATIVE
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
WO2006117221A1 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
UA92608C2 (en) 2005-06-30 2010-11-25 Янссен Фармацевтика Н.В. Cyclic anilino - pyridinotriazines as gsk-3 inhibitors
WO2007008514A2 (en) 2005-07-07 2007-01-18 Georgetown University Inhibitors of glycogen synthase kinase 3
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
WO2007089193A1 (en) 2006-02-02 2007-08-09 Astrazeneca Ab A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof
WO2007089192A1 (en) 2006-02-02 2007-08-09 Astrazeneca Ab Pharmaceutical use of 2-hydroxy-3- [5- (morpholin-4- ylmethyl) pyridine-2-yl] -1h- indole-5-carbonitrile as a free base or salts
CN101389623A (zh) 2006-02-28 2009-03-18 阿斯利康(瑞典)有限公司 吲哚衍生物的新的盐及其在医药中的用途
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
AU2007225088B2 (en) 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
WO2007120102A1 (en) 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
US7851468B2 (en) 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
CA2661334C (en) 2006-08-23 2011-11-29 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2010513386A (ja) 2006-12-19 2010-04-30 ノバルティス アーゲー キナーゼ阻害剤としてのインドリルマレイミド誘導体
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
CN101679353A (zh) 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 制备化合物2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈701的新方法
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
DE102007032977A1 (de) 2007-07-16 2009-01-22 Universität Tübingen Neue Cyclische Amide, Verfahren zu deren Herstellung und ihre Verwendung
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
CA2699151A1 (en) 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
KR101597841B1 (ko) 2007-09-12 2016-02-26 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
ES2418457T3 (es) 2008-04-24 2013-08-13 Abbott Gmbh & Co. Kg Derivados de 1-(7-(hexahidropirrolo[3,4-c]pirrol-2(1H)-il)quinolin-4-il)-3-(pirazin-2-il)urea y compuestos relacionados como inhibidores de glucógeno sintasa cinasa 3 (GSK-3)
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
US20090291982A1 (en) 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
US20130039998A1 (en) 2008-12-24 2013-02-14 University Of Washington Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
CA2755120C (en) 2009-03-11 2017-05-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
JP5699129B2 (ja) 2009-04-14 2015-04-08 イーライ リリー アンド カンパニー 造血器新生物および白血病の治療のためのベンゾジアゼピン誘導体
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
US8198285B2 (en) 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
DE102011081172B4 (de) 2011-08-18 2013-05-08 Schott Ag Verpackungseinheit für ein auf einen Wickelkern gerolltes Glas
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2765188B1 (en) 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
EP2838888B1 (en) 2012-02-24 2017-04-12 ASD Therapeutics Partners LLC Thiadiazolidinediones as gsk-3 inhibitors
TW201406758A (zh) 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
GB201212960D0 (en) 2012-07-20 2012-09-05 Common Services Agency Erythroid production
WO2014050779A1 (ja) 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
DK2909204T3 (en) 2012-10-12 2019-04-01 Broad Inst Inc GSK3 INHIBITORS AND METHODS FOR USE THEREOF
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
CN105143445B (zh) 2012-11-29 2020-07-07 宝生物欧洲公司 衍生自人多能干细胞的肝细胞样细胞的成熟
JP2017500287A (ja) 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
US20190093079A1 (en) * 2016-03-02 2019-03-28 Frequency Therapeutics, Inc. Methods for controlled proliferation of stem cells / generating inner ear hair cells using gsk-3-alpha inhibitors
ES2896938T3 (es) 2016-11-28 2022-02-28 Bristol Myers Squibb Co Inhibidores de GSK-3
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP3592747A1 (en) 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof

Similar Documents

Publication Publication Date Title
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP2022523700A5 (enExample)
JP6357131B2 (ja) 性機能不全の治療におけるテストステロンおよび５−ｈｔ１ａアゴニストの使用
JP2023065398A (ja) リルゾールの舌下製剤
US20110245235A1 (en) Systems, Methods, and Devices for Rehabilitation of Auditory System Disorders Using Pharmaceutical Agents and Auditory Devices
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
EP4494700A3 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
Staecker et al. Selecting appropriate dose regimens for AM-101 in the intratympanic treatment of acute inner ear tinnitus
WO2022132189A1 (en) Bdnf otic formulations and use thereof
JP2024516003A (ja) 糖尿病網膜症および関連する状態を治療するための方法および組成物
WO2021050692A2 (en) Methods for alleviating pterygium-associated worry about eye appearance
JP7158723B2 (ja) 耳疾患の処置における使用のための（＋）－アザセトロン
US20220323343A1 (en) Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia
JP2025525990A (ja) 感音難聴の治療のためのｂｄｎｆの鼻腔内投与
EP3920885A1 (en) Valproic acid compounds and wnt agonists for treating ear disorders
US11116719B2 (en) Methods of treating Meniere's disease
DE102006027795A1 (de) Raucherentwöhnungs-Kombinationswafer
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤
Acioglu et al. Ototoxicity associated with topical administration of diclofenac sodium as an otic drop: An experimental animal study
WO2021127275A1 (en) Gsk-3 modulator otic formulations
AU2019208152B2 (en) Treatment method
RU2779973C1 (ru) Способ профилактики нарушений слуховой функции у человека при воздействии шума
JP5978471B2 (ja) 耳鳴患者の治療用の薬剤
Yassin et al. Sensory neural deafness in pellagra
Kitahara et al. Vestibular symptoms and ENG findings during periods of convalescence after endolymphatic sac drainage and steroid-instillation surgery (EDSS)